Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bacillus subtilis compound plus sevelamer carbonate for hyperphosphatemia in CKD-MBD
ChiCTR2600133276Phase 4Recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bacillus subtilis and sevelamer carbonate in chronic kidney disease-mineral and bone disorder (CKD-MBD) and hyperphosphatemia (2 arms), sponsored by Yibin Second People's Hospital. Primary endpoint: Change in serum phosphorus concentration from baseline to week 12. Started Oct 2025; status: recruiting.
02
Drugs
bacillus subtilissevelamer carbonate
03
Conditions
chronic kidney disease-mineral and bone disorder (CKD-MBD)hyperphosphatemia
Beyond the preview
Go deeper on ChiCTR2600133276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133276.